Skip to main content

Table 4 Day 0 prevalence of different Pfmdr1 single nucleotide polymorphisms at the four sites covered in the therapeutic efficacy study in 2016

From: Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania

SNP Kibaha Mkuzi Mlimba Ujiji Total
N86a 79 (98.8) 87 (98.9) 87 (98.9) 88 (100.0) 341 (99.1)
184F 34 (42.5) 41 (46.6) 30 (34.1) 32 (36.4) 137 (39.8)
D1246 80 (100.0) 87 (98.9) 87 (98.9) 88 (100.0) 342 (99.4)
  1. aOne sample from Mlimba had an N86I mutation while the others with mutations at this SNP possessed N86Y (2 samples, one each from Kibaha and Mkuzi)